Dr. Petrylak on whether baseline PSA level should affect use of enzalutamide/ADT in mHSPC patients who had prior ADT

Daniel P. Petrylak, MD, professor of Medicine and Urology, coleader, Cancer Signaling Networks, Yale Cancer Center, discusses the abstract, “Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES,” which he shared at the 2022 ESMO Congress (abstract 1398P).